Hormone therapy for certain early uterine lining cancers without obesity
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your biopsy or hysteroscopy confirmed either atypical endometrial hyperplasia (EAH) or low-grade stage 1 endometrial cancer (G1) with no tumor spread into the muscle layer
- Your BMI is under 30
- Imaging (MRI/CT/ultrasound) does not show spread outside the uterus
- You previously tried progestin treatment, and it either stayed stable after about 7 months or did not fully clear after about 10 months
- You need or want to keep your reproductive function or uterus
- You are able to follow the treatment and follow-up plan closely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This trial tests adding orlistat to standard hormone therapy for people with early endometrial cancer or atypical hyperplasia who have not fully responded to initial hormone treatment. It aims to preserve fertility and avoid hysterectomy.
This trial tests whether medroxyprogesterone acetate (a progesterone hormone) plus atorvastatin (a cholesterol medicine) can treat early, limited problems in the womb lining—either atypical hyperplasia or early cancer (Grade 1) that has not spread into the muscle wall. It may help shrink or clear the abnormal tissue while supporting keeping fertility and the uterus.
This study tests whether a three-month program that includes weight-loss medications and hormone therapy before surgery is better than surgery alone for women with early-stage endometrial cancer and severe obesity. The goal is to see if this approach improves surgical outcomes and overall health.
This trial tests combining a weight-loss medication (mazdutide) with a hormone-releasing intrauterine device (LNG-IUS) to treat early-stage uterine cancer or precancerous changes while preserving fertility. It aims to help patients who are overweight or obese and wish to avoid hysterectomy.
Hear when a new Endometrial Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.